{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T05:22:20Z","timestamp":1792905740293,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1245\/s10434-025-18191-y","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T17:43:52Z","timestamp":1756230232000},"page":"8946-8957","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Accuracy of PET\u2013CT to Assess the Extent of Nodal Disease in Patients with Clinical Stage III Melanoma Following Neoadjuvant Treatment"],"prefix":"10.1245","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4796-9148","authenticated-orcid":false,"given":"Ronen","family":"Stoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Yalon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Thorpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Flotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Block","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina J.","family":"Hieken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,26]]},"reference":[{"key":"18191_CR1","unstructured":"SEER*Explorer: An interactive website for SEER cancer statistics [Internet]. Surveillance Research Program, National Cancer Institute; 2024 Apr 17. Available from: https:\/\/seer.cancer.gov\/statistics-network\/explorer\/. Data source(s): SEER Incidence Data, November 2023 Submission (1975-2021), SEER 22 registries. Accessed 9 May 2024. https:\/\/seer.cancer.gov\/statistics-network\/explorer\/application.html?site=53&data_type=1&graph_type=4&compareBy=sex&chk_sex_3=3&chk_sex_2=2&race=1&age_range=1&advopt_precision=1&hdn_view=0&advopt_show_apc=on&advopt_display=2#resultsRegion0"},{"issue":"4","key":"18191_CR2","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/jso.21962","volume":"104","author":"MI Ross","year":"2011","unstructured":"Ross MI, Gershenwald JE. Evidence-based treatment of early-stage melanoma. J Surg Oncol. 2011;104(4):341\u201353. https:\/\/doi.org\/10.1002\/jso.21962.","journal-title":"J Surg Oncol."},{"issue":"1","key":"18191_CR3","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jaad.2018.08.055","volume":"80","author":"SM Swetter","year":"2019","unstructured":"Swetter SM, Tsao H, Bichakjian CK, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019;80(1):208\u201350. https:\/\/doi.org\/10.1016\/j.jaad.2018.08.055.","journal-title":"J Am Acad Dermatol."},{"key":"18191_CR4","unstructured":"AJCC Cancer Staging Manual. Accessed 4 April 2024. https:\/\/link.springer.com\/book\/9783319406176"},{"issue":"16","key":"18191_CR5","doi-asserted-by":"publisher","first-page":"3622","DOI":"10.1200\/JCO.2001.19.16.3622","volume":"19","author":"CM Balch","year":"2001","unstructured":"Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer Melanoma Staging System. JCO. 2001;19(16):3622\u201334. https:\/\/doi.org\/10.1200\/JCO.2001.19.16.3622.","journal-title":"JCO."},{"issue":"11","key":"18191_CR6","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","volume":"21","author":"PA Ascierto","year":"2020","unstructured":"Ascierto PA, Del Vecchio M, Mandal\u00e1 M, et al. Adjuvant nivolumab versus ipilimumab in resected stage IIIB\u2013C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2020;21(11):1465\u201377. https:\/\/doi.org\/10.1016\/S1470-2045(20)30494-0.","journal-title":"Lancet Oncol."},{"issue":"33","key":"18191_CR7","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1200\/JCO.20.02110","volume":"38","author":"AMM Eggermont","year":"2020","unstructured":"Eggermont AMM, Blank CU, Mandala M, et al. Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: updated results from the EORTC 1325-MG\/KEYNOTE-054 Trial. JCO. 2020;38(33):3925\u201336. https:\/\/doi.org\/10.1200\/JCO.20.02110.","journal-title":"JCO."},{"issue":"12","key":"18191_CR8","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa2005493","volume":"383","author":"R Dummer","year":"2020","unstructured":"Dummer R, Hauschild A, Santinami M, et al. Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma. N Engl J Med. 2020;383(12):1139\u201348. https:\/\/doi.org\/10.1056\/NEJMoa2005493.","journal-title":"N Engl J Med."},{"issue":"12","key":"18191_CR9","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1158\/2159-8290.CD-16-0577","volume":"6","author":"J Liu","year":"2016","unstructured":"Liu J, Blake SJ, Yong MCR, et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discovery. 2016;6(12):1382\u201399. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-0577.","journal-title":"Cancer Discovery."},{"key":"18191_CR10","doi-asserted-by":"publisher","first-page":"175883592210830","DOI":"10.1177\/17588359221083052","volume":"14","author":"RG Witt","year":"2022","unstructured":"Witt RG, Erstad DJ, Wargo JA. Neoadjuvant therapy for melanoma: rationale for neoadjuvant therapy and pivotal clinical trials. Ther Adv Med Oncol. 2022;14:17588359221083052. https:\/\/doi.org\/10.1177\/17588359221083052.","journal-title":"Ther Adv Med Oncol."},{"issue":"9","key":"18191_CR11","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMoa2211437","volume":"388","author":"SP Patel","year":"2023","unstructured":"Patel SP, Othus M, Chen Y, et al. Neoadjuvant\u2013adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N Engl J Med. 2023;388(9):813\u201323. https:\/\/doi.org\/10.1056\/NEJMoa2211437.","journal-title":"N Engl J Med."},{"issue":"7","key":"18191_CR12","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/S1470-2045(19)30151-2","volume":"20","author":"EA Rozeman","year":"2019","unstructured":"Rozeman EA, Menzies AM, van Akkooi ACJ, et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol. 2019;20(7):948\u201360. https:\/\/doi.org\/10.1016\/S1470-2045(19)30151-2.","journal-title":"Lancet Oncol."},{"key":"18191_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ejca.2021.02.012","volume":"148","author":"JM Versluis","year":"2021","unstructured":"Versluis JM, Reijers ILM, Rozeman EA, et al. Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma. Eur J Cancer. 2021;148:51\u20137. https:\/\/doi.org\/10.1016\/j.ejca.2021.02.012.","journal-title":"Eur J Cancer."},{"issue":"6","key":"18191_CR14","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41591-022-01851-x","volume":"28","author":"ILM Reijers","year":"2022","unstructured":"Reijers ILM, Menzies AM, van Akkooi ACJ, et al. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nat Med. 2022;28(6):1178\u201388. https:\/\/doi.org\/10.1038\/s41591-022-01851-x.","journal-title":"Nat Med."},{"issue":"7934","key":"18191_CR15","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41586-022-05368-8","volume":"611","author":"RN Amaria","year":"2022","unstructured":"Amaria RN, Postow M, Burton EM, et al. Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature. 2022;611(7934):155\u201360. https:\/\/doi.org\/10.1038\/s41586-022-05368-8.","journal-title":"Nature."},{"issue":"7","key":"18191_CR16","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/S1470-2045(19)30331-6","volume":"20","author":"GV Long","year":"2019","unstructured":"Long GV, Saw RPM, Lo S, et al. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB\u2013C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. Lancet Oncol. 2019;20(7):961\u201371. https:\/\/doi.org\/10.1016\/S1470-2045(19)30331-6.","journal-title":"Lancet Oncol."},{"issue":"1","key":"18191_CR17","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1038\/s41467-024-45798-8","volume":"15","author":"TJ Hieken","year":"2024","unstructured":"Hieken TJ, Nelson GD, Flotte TJ, et al. Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial. Nat Commun. 2024;15(1):1430. https:\/\/doi.org\/10.1038\/s41467-024-45798-8.","journal-title":"Nat Commun."},{"issue":"8","key":"18191_CR18","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1093\/annonc\/mdy226","volume":"29","author":"MT Tetzlaff","year":"2018","unstructured":"Tetzlaff MT, Messina JL, Stein JE, et al. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Ann Oncol. 2018;29(8):1861\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdy226.","journal-title":"Ann Oncol."},{"issue":"2","key":"18191_CR19","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41591-020-01188-3","volume":"27","author":"AM Menzies","year":"2021","unstructured":"Menzies AM, Amaria RN, Rozeman EA, et al. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat Med. 2021;27(2):301\u20139. https:\/\/doi.org\/10.1038\/s41591-020-01188-3.","journal-title":"Nat Med."},{"key":"18191_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.05.002","author":"AM Menzies","year":"2024","unstructured":"Menzies AM, Lo SN, Saw RPM, et al. Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma. Ann Oncol. 2024. https:\/\/doi.org\/10.1016\/j.annonc.2024.05.002.","journal-title":"Ann Oncol."},{"issue":"11","key":"18191_CR21","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.annonc.2020.07.016","volume":"31","author":"MT Tetzlaff","year":"2020","unstructured":"Tetzlaff MT, Adhikari C, Lo S, et al. Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma. Ann Oncol. 2020;31(11):1569\u201379. https:\/\/doi.org\/10.1016\/j.annonc.2020.07.016.","journal-title":"Ann Oncol."},{"key":"18191_CR22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402604","author":"CU Blank","year":"2024","unstructured":"Blank CU, Lucas MW, Scolyer RA, et al. Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma. N Engl J Med. 2024. https:\/\/doi.org\/10.1056\/NEJMoa2402604.","journal-title":"N Engl J Med."},{"issue":"2","key":"18191_CR23","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/s41591-020-01211-7","volume":"27","author":"EA Rozeman","year":"2021","unstructured":"Rozeman EA, Hoefsmit EP, Reijers ILM, et al. Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. Nat Med. 2021;27(2):256\u201363. https:\/\/doi.org\/10.1038\/s41591-020-01211-7.","journal-title":"Nat Med."},{"issue":"1","key":"18191_CR24","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41591-024-03411-x","volume":"31","author":"R Dummer","year":"2025","unstructured":"Dummer R, Robert C, Scolyer RA, et al. Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB\u2013D melanoma: a phase 1\/2 trial. Nat Med. 2025;31(1):144\u201351. https:\/\/doi.org\/10.1038\/s41591-024-03411-x.","journal-title":"Nat Med."},{"issue":"1","key":"18191_CR25","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s13046-024-03153-1","volume":"43","author":"WY Chan","year":"2024","unstructured":"Chan WY, Lee JH, Stewart A, et al. Circulating tumour DNA dynamics predict recurrence in stage III melanoma patients receiving neoadjuvant immunotherapy. J Exp Clin Cancer Res. 2024;43(1):238. https:\/\/doi.org\/10.1186\/s13046-024-03153-1.","journal-title":"J Exp Clin Cancer Res."},{"issue":"10","key":"18191_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2023.06.002","volume":"49","author":"E Mor","year":"2023","unstructured":"Mor E, Schtrechman G, Nizri E, et al. PET-CT underestimates the true pathological extent of disease at lymphadenectomy for melanoma patients after systemic therapy. Eur J Surg Oncol. 2023;49(10):106950. https:\/\/doi.org\/10.1016\/j.ejso.2023.06.002.","journal-title":"Eur J Surg Oncol."},{"issue":"7","key":"18191_CR27","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1097\/RLU.0000000000004217","volume":"47","author":"B van der Hiel","year":"2022","unstructured":"van der Hiel B, Blankenstein SA, Aalbersberg EA, et al. 18F-FDG PET\/CT during neoadjuvant targeted therapy in prior unresectable stage III melanoma patients: can (early) metabolic imaging predict histopathologic response or recurrence? Clin Nucl Med. 2022;47(7):583. https:\/\/doi.org\/10.1097\/RLU.0000000000004217.","journal-title":"Clin Nucl Med."},{"issue":"5","key":"18191_CR28","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1007\/s00330-021-08355-1","volume":"32","author":"A Annovazzi","year":"2022","unstructured":"Annovazzi A, Ferraresi V, Rea S, et al. Prognostic value of total metabolic tumour volume and therapy-response assessment by [18F]FDG PET\/CT in patients with metastatic melanoma treated with BRAF\/MEK inhibitors. Eur Radiol. 2022;32(5):3398\u2013407. https:\/\/doi.org\/10.1007\/s00330-021-08355-1.","journal-title":"Eur Radiol."},{"key":"18191_CR29","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_390614","volume":"43","author":"TJ Hieken","year":"2023","unstructured":"Hieken TJ, Kreidieh F, Aedo-Lopez V, Block MS, McArthur GA, Amaria RN. Neoadjuvant immunotherapy in melanoma: the paradigm shift. Am Soc Clin Oncol Educ Book. 2023;43:e390614. https:\/\/doi.org\/10.1200\/EDBK_390614.","journal-title":"Am Soc Clin Oncol Educ Book."},{"issue":"2","key":"18191_CR30","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer."},{"issue":"13","key":"18191_CR31","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","volume":"35","author":"H Young","year":"1999","unstructured":"Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur J Cancer. 1999;35(13):1773\u201382. https:\/\/doi.org\/10.1016\/S0959-8049(99)00229-4.","journal-title":"Eur J Cancer."},{"issue":"2","key":"18191_CR32","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1148\/radiol.2016142043","volume":"280","author":"MA Lodge","year":"2016","unstructured":"Lodge MA, Wahl RL. Practical PERCIST: a simplified guide to PET response criteria in solid tumors 10. Radiology. 2016;280(2):576\u201384. https:\/\/doi.org\/10.1148\/radiol.2016142043.","journal-title":"Radiology."},{"issue":"3","key":"18191_CR33","doi-asserted-by":"publisher","first-page":"595","DOI":"10.3390\/diagnostics12030595","volume":"12","author":"KN Hlongwa","year":"2022","unstructured":"Hlongwa KN, Mokoala KMG, Matsena-Zingoni Z, Vorster M, Sathekge MM. The use of 18F-FDG PET\/CT metabolic parameters in predicting overall survival in patients undergoing restaging for malignant melanoma. Diagnostics. 2022;12(3):595. https:\/\/doi.org\/10.3390\/diagnostics12030595.","journal-title":"Diagnostics."},{"issue":"12","key":"18191_CR34","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.annonc.2023.10.001","volume":"34","author":"L Castelo-Branco","year":"2023","unstructured":"Castelo-Branco L, Pellat A, Martins-Branco D, et al. ESMO guidance for reporting oncology real-world evidence (GROW). Ann Oncol. 2023;34(12):1097\u2013112. https:\/\/doi.org\/10.1016\/j.annonc.2023.10.001.","journal-title":"Ann Oncol."},{"issue":"4","key":"18191_CR35","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011706","volume":"13","author":"MS Block","year":"2025","unstructured":"Block MS, Nelson GD, Chen J, et al. Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial. J Immunother Cancer. 2025;13(4):e011706. https:\/\/doi.org\/10.1136\/jitc-2025-011706.","journal-title":"J Immunother Cancer."},{"key":"18191_CR36","unstructured":"NCCN guidelines Version 2.2025 Melanoma-Cutaneous. Accessed 4 February 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cutaneous_melanoma.pdf"},{"issue":"30","key":"18191_CR37","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.1200\/JCO.23.01136","volume":"41","author":"R Seth","year":"2023","unstructured":"Seth R, Agarwala SS, Messersmith H, et al. Systemic therapy for melanoma: ASCO guideline update. JCO. 2023;41(30):4794\u2013820. https:\/\/doi.org\/10.1200\/JCO.23.01136.","journal-title":"JCO."},{"key":"18191_CR38","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-011483","author":"L Zhou","year":"2025","unstructured":"Zhou L, Silva MJB, Hsiao E, et al. FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanoma. J Immunother Cancer. 2025. https:\/\/doi.org\/10.1136\/jitc-2025-011483.","journal-title":"J Immunother Cancer."},{"key":"18191_CR39","doi-asserted-by":"publisher","first-page":"S1232","DOI":"10.1016\/j.annonc.2024.08.2282","volume":"35","author":"GV Long","year":"2024","unstructured":"Long GV, Blank CU, Amaria RN, et al. LBA41 Long-term survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Ann Oncol. 2024;35:S1232. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2282.","journal-title":"Ann Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18191-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-18191-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18191-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T15:41:08Z","timestamp":1760715668000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-18191-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["18191"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-18191-y","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,26]]},"assertion":[{"value":"19 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Matthew Block: institutional research support from Genentech. Institutional research support from Alkermes, Bristol-Myers Squibb, Merck, nFerence, Perspective Therapeutics, Pharmacyclics, Regeneron, Sorrento, TILT Biotherapeutics, and Transgene. (Unpaid) consultant for Perspective Therapeutics, Sorrento Therapeutics, and TILT Biotherapeutics. Inventor on patents filed by Mayo Clinic: \u201cDendritic Cell-Based Vaccines and Uses Thereof,\u201d and \u201cCombinations of Dendritic Cell-Based Vaccines and Checkpoint Inhibitors.\u201d Tina Hieken: research funding to my institution from Genentech. Research funding to my institution from SkylineDx.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}